A Phase II Pilot Study of Bortezomib (PS-341, Velcade) Combined With Reinduction Chemotherapy in Children and Young Adults With Recurrent, Refractory or Secondary Acute Myeloid Leukemia.

Trial Profile

A Phase II Pilot Study of Bortezomib (PS-341, Velcade) Combined With Reinduction Chemotherapy in Children and Young Adults With Recurrent, Refractory or Secondary Acute Myeloid Leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2013

At a glance

  • Drugs Bortezomib (Primary) ; Cytarabine; Cytarabine; Etoposide phosphate; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Feb 2013 New source identified and integrated (Mayo Clinic; 09-001131).
    • 03 Dec 2012 Actual end date changed from Jan 2012 to Dec 2012, as reported by ClinicalTrials.gov.
    • 03 Aug 2012 Planned end date changed from 1 Aug 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top